Chinese Journal of Antituberculosis ›› 2022, Vol. 44 ›› Issue (3): 219-226.doi: 10.19982/j.issn.1000-6621.20210696
• Original Articles • Previous Articles Next Articles
XIE Li1, ZHU Hui2, GAO Jing-tao3, LIU Zhong-quan2, MA Li-ping1, ZHANG Li-qun1, GE Qi-ping1, NIE Li-hui1, KONG Zhong-shun1, WU Xiao-guang1, LIU Rong-mei1, CHEN Hong-mei1, SONG Yan-hua1, LI Qiang1, LYU Zi-zheng1, LIU Yu-hong3(), LU Yu2(), PANG Yu4(), GAO Meng-qiu1()
Received:
2021-12-08
Online:
2022-03-10
Published:
2022-03-08
Contact:
LIU Yu-hong,LU Yu,PANG Yu,GAO Meng-qiu
E-mail:liuyuhong0516@126.com;luyu4876@hotmail.com;pangyupound@163.com;gaomengqiu@hotmail.com
Supported by:
CLC Number:
XIE Li, ZHU Hui, GAO Jing-tao, LIU Zhong-quan, MA Li-ping, ZHANG Li-qun, GE Qi-ping, NIE Li-hui, KONG Zhong-shun, WU Xiao-guang, LIU Rong-mei, CHEN Hong-mei, SONG Yan-hua, LI Qiang, LYU Zi-zheng, LIU Yu-hong, LU Yu, PANG Yu, GAO Meng-qiu. Changes of plasma concentration of bedaquiline during the treatment of drug-resistant pulmonary tuberculosis and its assocation with QTc interval prolongation[J]. Chinese Journal of Antituberculosis, 2022, 44(3): 219-226. doi: 10.19982/j.issn.1000-6621.20210696
Add to citation manager EndNote|Ris|BibTeX
URL: http://www.zgflzz.cn/EN/10.19982/j.issn.1000-6621.20210696
组别 | 2周末b | 2周末c | 4周末b | 4周末c | 8周末 | 12周末 | 16周末 | 20周末 | 24周末 | 36周末 | 48周末 | 60周末 | 72周末 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
24周组 (53例) | 4.108 (3.163, 5.382) | 1.922 (1.478, 2.620) | 2.277 (1.758, 3.057) | 0.871 (0.650, 1.152) | 0.921 (0.718, 1.237) | 0.983 (0.769, 1.280) | 1.138 (0.853, 1.352) | 1.184 (0.916, 1.513) | 1.239 (0.988, 1.569) | 0.769 (0.500, 0.947) | 0.531 (0.384, 0.736) | 0.350 (0.203, 0.532) | - |
36周组 (61例) | 4.464 (3.626, 5.669) | 1.654 (1.290, 2.285) | 2.419 (1.663, 3.204) | 0.786 (0.564, 1.000) | 0.826 (0.614, 1.061) | 0.875 (0.667, 1.104) | 0.932 (0.707, 1.164) | 0.965 (0.748, 1.212) | 1.015 (0.793, 1.280) | 1.259 (0.880, 1.632) | 0.824 (0.642, 1.023) | 0.598 (0.424, 0.776) | 0.336 (0.221, 0.485) |
合计 (114例)a | 4.388 (3.338, 5.479) | 1.753 (1.365, 2.412) | 2.394 (1.677, 3.109) | 0.830 (0.586, 1.035) | 0.869 (0.624, 1.121) | 0.934 (0.675, 1.195) | 1.056 (0.756, 1.307) | 1.071 (0.857, 1.378) | 1.098 (0.909, 1.440) | 0.947 (0.738, 1.392) | 0.686 (0.497, 0.927) | 0.505 (0.300, 0.673) | 0.336 (0.221, 0.485) |
组别 | 0周 | 2周末 | 4周末 | 8周末 | 12周末 | 16周末 | 20周末 | 24周末 | 36周末 | 48周末 | 60周末 | 72周末 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
24周组 (53例) | 400.980 ±17.959 | 409.921 ±19.516 | 415.728 ±16.684 | 416.920 ±20.015 | 417.835 ±29.322 | 423.287 ±32.151 | 424.248 ±39.047 | 424.386 ±27.984 | 419.628 ±21.740 | 423.890 ±26.614 | 414.284 ±20.336 | 410.491 ±23.133 |
36周组 (61例) | 405.002 ±15.934 | 413.898 ±22.326 | 410.903 ±18.620 | 412.342 ±19.320 | 413.510 ±18.266 | 416.890 ±22.936 | 418.215 ±21.524 | 414.666 ±21.571 | 424.722 ±28.950 | 417.628 ±22.192 | 415.036 ±22.842 | 411.953 ±20.025 |
合计 (114例) | 403.133 ±16.949 | 412.045 ±21.069 | 413.141 ±17.832 | 414.700 ±19.703 | 415.527 ±24.031 | 419.703 ±27.763 | 421.039 ±30.949 | 419.184 ±25.123 | 422.356 ±25.866 | 420.542 ±24.439 | 414.688 ±21.622 | 411.271 ±21.441 |
变量 | 例数 | QTc间期延长 [例(发生率,%)] | χ2值 | P值 |
---|---|---|---|---|
年龄组(岁) | 7.395 | 0.007 | ||
18~54 | 71 | 25(35.2) | ||
≥55 | 15 | 11(73.3) | ||
性别 | 0.108 | 0.742 | ||
男性 | 59 | 24(40.7) | ||
女性 | 27 | 12(44.4) | ||
体质量指数 | 19.92 | <0.001 | ||
<18.5 | 20 | 17(85.0) | ||
≥18.5 | 66 | 19(28.8) | ||
合并应用氟喹诺酮类药物和(或)氯法齐明 | 6.441 | 0.011 | ||
是 | 74 | 35(47.3) | ||
否 | 12 | 1(8.3) | ||
血清钾浓度(mmol/L) | - | 0.394a | ||
<3.5 | 6 | 1(1/6) | ||
≥3.5 | 80 | 35(43.8) | ||
血清钙浓度(mmol/L) | 4.336 | 0.037 | ||
<2.3 | 32 | 18(56.3) | ||
≥2.3 | 54 | 18(33.3) | ||
血清镁浓度(mmol/L) | 2.657 | 0.103 | ||
<0.8 | 32 | 17(53.1) | ||
≥0.8 | 54 | 19(35.2) |
[1] |
Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment—2017, Ahmad N, Ahuja SD, et al. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis:an individual patient data meta-analysis. Lancet, 2018, 392(10150):821-834. doi: 10.1016/S0140-6736(18)31644-1.
doi: 10.1016/S0140-6736(18)31644-1 URL |
[2] |
Olayanju O, Limberis J, Esmail A, et al. Long-term bedaquiline-related treatment outcomes in patients with extensively drug-resistant tuberculosis from South Africa. Eur Respir J, 2018, 51(5):1800544. doi: 10.1183/13993003.00544-2018.
doi: 10.1183/13993003.00544-2018 URL |
[3] |
Monedero-Recuero I, Hernando-Marrupe L, Sánchez-Montalvá A, et al. QTc and anti-tuberculosis drugs: a perfect storm or a tempest in a teacup? Review of evidence and a risk assessment. Int J Tuberc Lung Dis, 2018. doi: 10.5588/ijtld.18.0423.
doi: 10.5588/ijtld.18.0423 |
[4] | World Health Organization. WHO consolidated guidelines on tuberculosis.Module 4;treatment-drug-resistan tuberculosis treatment. Geneva:World Health Organization, 2020. |
[5] |
中国防痨协会. 耐药结核病化学治疗指南(2019年简版). 中国防痨杂志, 2019, 41(10):1025-1073. doi: 10.3969/j.issn.1000-6621.2019.10.001.
doi: 10.3969/j.issn.1000-6621.2019.10.001 |
[6] |
中华医学会结核病学分会. 中国耐多药和利福平耐药结核病治疗专家共识(2019年版). 中华结核和呼吸杂志, 2019, 42(10):733-749. doi: 10.3760/cma.j.issn.1001-0939.2019.10.006.
doi: 10.3760/cma.j.issn.1001-0939.2019.10.006 |
[7] |
Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med, 2009, 360(23):2397-2405. doi: 10.1056/NEJMoa0808427.
doi: 10.1056/NEJMoa0808427 URL |
[8] | World Health Organization. Global tuberculosis report 2020. Geneva:World Health Organization, 2020. |
[9] | World Health Organization. Global tuberculosis report 2018. Geneva:World Health Organization, 2018. |
[10] | World Health Organization. Global tuberculosis report 2019. Geneva:World Health Organization, 2019. |
[11] |
中华医学会结核病学分会. 抗结核新药贝达喹啉临床应用专家共识(2020年更新版). 中华结核和呼吸杂志, 2021, 44(2):81-87. doi: 10.3760/cma.j.cn112147-20200714-00805.
doi: 10.3760/cma.j.cn112147-20200714-00805 |
[12] |
首都医科大学附属北京胸科医院, 《中国防痨杂志》编辑委员会. 抗结核药治疗药物监测临床应用专家共识. 中国防痨杂志, 2021, 43(9):867-873. doi: 10.3969/j.issn.1000-6621.2021.09.003.
doi: 10.3969/j.issn.1000-6621.2021.09.003 |
[13] |
Märtson AG, Burch G, Ghimire S, et al. Therapeutic drug monitoring in patients with tuberculosis and concurrent medical problem. Expert Opin Drug Metab Toxicol, 2021, 17(1):23-29. doi: 10.1080/17425255.2021.1836158.
doi: 10.1080/17425255.2021.1836158 URL |
[14] |
Nahid P, Mase SR, Migliori GB, et al. Treatment of Drug-Resistant Tuberculosis.An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline. Am J Respir Crit Care Med, 2019, 200(10):e93-e142. doi: 10.1164/rccm.201909-1874ST.
doi: 10.1164/rccm.201909-1874ST URL |
[15] |
Diacon AH, Donald PR, Pym A, et al. Randomized pilot trial of eight weeks of bedaquiline(TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome,tolerability,and effect on emergence of drug resistance. Antimicrob Agents Chemother, 2012, 56(6):3271-3276. doi: 10.1128/AAC.06126-11.
doi: 10.1128/AAC.06126-11 pmid: 22391540 |
[16] |
Svensson EM, Dosne AG, Karlsson MO. Population Pharmacokinetics of Bedaquiline and Metabolite M2 in Patients With Drug-Resistant Tuberculosis: The Effect of Time-Varying Weight and Albumin. CPT pharmacometrics Syst Pharmacol, 2016, 5(12):682-691. doi: 10.1002/psp4.12147.
doi: 10.1002/psp4.12147 URL |
[17] |
van Heeswijk RP, Dannemann B, Hoetelmans RM. Bedaquiline: a review of human pharmacokinetics and drug-drug interactions. J Antimicrob Chemother, 2014, 69(9):2310-2318. doi: 10.1093/jac/dku171.
doi: 10.1093/jac/dku171 pmid: 24860154 |
[18] |
Perrineau S, Lachâtre M, Lê MP, et al. Long-term plasma pharmacokinetics of bedaquiline for multidrug- and extensively drug-resistant tuberculosis. Int J Tuberc Lung Dis, 2019, 23(1):99-104. doi: 10.5588/ijtld.18.0042.
doi: 10.5588/ijtld.18.0042 pmid: 30674381 |
[19] |
Tisdale JE. Drug-induced QT interval prolongation and torsades de pointes: Role of the pharmacist in risk assessment, prevention and management. Can Pharm J (Ott), 2016, 149(3):139-152. doi: 10.1177/1715163516641136.
doi: 10.1177/1715163516641136 |
[20] |
Hincapie-Castillo JM, Staley B, Henriksen C, et al. Development of a predictive model for drug-associated QT prolongation in the inpatient setting using electronic health record data. Am J Health Syst Pharm, 2019, 76(14):1059-1070. doi: 10.1093/ajhp/zxz100.
doi: 10.1093/ajhp/zxz100 URL |
[21] | Centers for Disease Control and Prevention. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis. MMWR Recomm Rep, 2013, 62(RR-09):1-12. |
[22] |
Moss AJ, Schwartz PJ, Crampton RS, et al. The long QT syndrome.Prospective longitudinal study of 328 families. Circulation, 1991, 84(3):1136-1144. doi: 10.1161/01.cir.84.3.1136.
doi: 10.1161/01.cir.84.3.1136 pmid: 1884444 |
[23] |
Sharma ND, Rosman HS, Padhi ID, et al. Torsades de pointes associated with intravenous haloperidol in critically ill patients. Am J Cardiol, 1998, 81(2):238-240. doi: 10.1016/s0002-9149(97)00888-6.
doi: 10.1016/s0002-9149(97)00888-6 pmid: 9591913 |
[24] |
Pratt CM, Singh SN, Al-Khalidi HR, et al. The efficacy of azimilide in the treatment of atrial fibrillation in the presence of left ventricular dysfunction: results from the Azimilide Postinfarct Survival Evaluation (ALIVE) trial. J Am Coll Cardiol, 2004, 43(7):1211-1216. doi: 10.1016/j.jacc.2003.10.057.
doi: 10.1016/j.jacc.2003.10.057 URL |
[25] |
Pontali E, Sotgiu G, Tiberi S, et al. Cardiac safety of bedaquiline:a systematic and critical analysis of the evidence. Eur Respiratory J, 2017, 50(5):1701462. doi: 10.1183/13993003.01462-2017.
doi: 10.1183/13993003.01462-2017 URL |
[26] |
Gueta I, Klempfner R, Markovits N, et al. Clinically significant incidental QTc prolongation is subject to within-individual variability. Ann Noninvasive Electrocardiol, 2020, 25(2):e12699. doi: 10.1111/anec.12699.
doi: 10.1111/anec.12699 |
[27] |
Trinkley KE, Page RL 2nd, Lien H, et al. QT interval prolongation and the risk of torsades de pointes: essentials for clinicians. Curr Med Res Opin, 2013, 29(12):1719-1726. doi: 10.1185/03007995.2013.840568.
doi: 10.1185/03007995.2013.840568 pmid: 24020938 |
[28] |
Postema PG, Wilde AA. The measurement of the QT interval. Curr Cardiol Rev, 2014, 10(3):287-294. doi: 10.2174/1573403x10666140514103612.
doi: 10.2174/1573403x10666140514103612 pmid: 24827793 |
[1] | LI Dong-shuo, WANG Bin, LU Yu, XU Jian. Study of expression and function of Mycobacterium tuberculosis membrane protein MmpL5-MmpS5 [J]. Chinese Journal of Antituberculosis, 2022, 44(3): 227-233. |
[2] | ZHANG Yu-xia, XIONG Yu, CHANG Ting-ting, LIU Feng-xia. Analysis of adverse reactions of bedaquiline containing regimen in the treatment of drug-resistant pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2022, 44(3): 239-245. |
[3] | QI Qi, CAI Qing-shan, CUI Yan-fei, CHEN Yuan-yuan, BAO Zhi-jian, QIU Mei-hua, GUO Yi-nan, MA Xiao-qing. Effect of Roast Radix Glycyrrhizae Decoction Granules on the prolongation of QT interval caused by bedaquiline in the treatment of multidrug-resistant pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2022, 44(3): 246-251. |
[4] | WU Guo-lan, GAO Jing-tao, CHEN Xiao-hong, CHEN Li-zhou, WENG Li-zhen, GUO Zhi-ping, CHEN Xiu-ping, LIN Jian-dong, CHEN Su-xia, GAO Meng-qiu, LIU Yu-hong. Short-term effectiveness and safety of a regimen containing bedaquiline in the treatment of multidrug-resistant/extensively drug-resistant tuberculosis [J]. Chinese Journal of Antituberculosis, 2021, 43(9): 899-904. |
[5] | DING Cai-hong, XIONG Yu, WANG Qing, GAO Xu-sheng, HAO Yan. Study on the early efficacy and safety of the regimen containing bedaquiline in the treatment of multidrug-resistant pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2021, 43(9): 893-898. |
[6] | Beijing Chest Hospital, Capital Medical University, Editorial Board of Chinese Journal of Antituberculosis. Expert consensus on the therapeutic drug monitoring of anti-tuberculosis drugs [J]. Chinese Journal of Antituberculosis, 2021, 43(9): 867-873. |
[7] | SHI Zheng-yu, WU Gui-hui, HUANG Tao, LIU Yu-hong, GAO Meng-qiu, CHEN Lei, LI Xi, YANG Ming, HE Wei, CHEN Yan, LU Xiao-li, GAO Jing-tao, LI Liang. Early effectiveness and safety of bedaquiline containing regimen in treatment of multidrug-resistant and extensively drug-resistant tuberculosis: An one arm observational study of 24 weeks [J]. Chinese Journal of Antituberculosis, 2021, 43(5): 487-494. |
[8] | WANG Lu, XUE Zhong-tan, WANG Yu-feng, SHANG Yuan-yuan, REN Wei-cong, YAO Cong, GAO Fei, PANG Yu. A study of dynamic monitoring of drug sensitivity of Mycobacterium tuberculosis to bedaquiline and the mechanism of drug resistance [J]. Chinese Journal of Antituberculosis, 2021, 43(5): 482-486. |
[9] | WANG Le-le, YANG Song, TANG Shen-jie. A review of application of therapeutic drug monitoring in tuberculosis treatment [J]. Chinese Journal of Antituberculosis, 2021, 43(3): 285-290. |
[10] | PEI Yi, GAO Jing-tao, HUANG Yun-hui, HE Fang, FENG Wen-jun, YANG Xiao-yun, HU Yu-meng, LEI Li-ping, SHI Li. Analysis of efficacy in the treatment of 44 pulmonary tuberculosis patients with mycobacterium culture-positive multidrug-resistant/extensively drug-resistant with bedaquiline-containing regimen for 24 weeks [J]. Chinese Journal of Antituberculosis, 2021, 43(11): 1139-1145. |
[11] | TIAN Dan, HU Xiao-meng, JIN Wu, CHENG Chang-hao, XIONG Lei-qun, HU Rong-hua, JIN Qian, LIU Yun, DU Juan. Sixty-seven MDR-,and XDR-PTB cases with sputum culture conversion then treated with bedaquiline-containing regimens: A singal arm, single center observational study [J]. Chinese Journal of Antituberculosis, 2021, 43(11): 1146-1152. |
[12] | SUN Qing, HUANG Hai-rong, WANG Gui-rong. In vitro activities and drug resistance mechanisms of bedaquiline, clofazimine and delamanid against common pathogenic non-tuberculous mycobacteria [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 880-884. |
[13] | XIE Li, GAO Jing-tao, MA Li-ping, ZHANG Li-qun, KONG Zhong-shun, WU Xiao-guang, LIU Rong-mei, CHEN Hong-mei, SONG Yan-hua, LI Xue-lian, Huang Mai-ling, LI Qiang, Lv Zi-zheng, LIu Yv-hong, Gao Meng-qiu. Effect of bedaquiline-containing regimen on QT interval in patients with multidrug-resistant tuberculosis [J]. Chinese Journal of Antituberculosis, 2020, 42(7): 687-694. |
[14] | FANG Xue-e, CHEN Dan-ping, TANG Ling-ling, FAN Lin, CHEN Wei, JI Hai-ming, MAO Yan-jun. Application effect of individual case management model during the process of taking bedaquiline in patients with MDR-PTB [J]. Chinese Journal of Antituberculosis, 2020, 42(6): 641-644. |
[15] | ZHANG Pei-ze, ZHENG Jun-feng, CAO Wei-peng, WANG Yu-xiang, CHEN Tao, FU Liang, DENG Guo-fang. Study of the serum concentration at two time points after taking rifampicin [J]. Chinese Journal of Antituberculosis, 2020, 42(5): 493-497. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||